openPR Logo
Press release

Multiple Myeloma Drugs Market Report 2024 - Multiple Myeloma Drugs Market Growth, Opportunities And Trends

11-29-2024 08:21 AM CET | Health & Medicine

Press release from: The Business research company

Multiple Myeloma Drugs Market

Multiple Myeloma Drugs Market

"The Business Research Company recently released a comprehensive report on the Global Multiple Myeloma Drugs Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp

According to The Business Research Company's, The multiple myeloma drugs market size has grown strongly in recent years. It will grow from $20.7 billion in 2023 to $22.09 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to improved diagnosis, clinical trials success, understanding disease biology, healthcare infrastructure improvements, patient advocacy and awareness.

The multiple myeloma drugs market size is expected to see strong growth in the next few years. It will grow to $28.07 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to immunotherapy innovations, targeted therapies expansion, liquid biopsy applications, emergence of car-t cell therapy, biomarker discovery. Major trends in the forecast period include long-term survivorship focus, exploration of epigenetic therapies, expanded role of telemedicine, expanded access to novel therapies, sustainability in myeloma care.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

Market Drivers and Trends:
The increasing prevalence of hematological cancer is expected to drive the growth of the multiple myeloma drugs market going forward. Hematological cancers start in blood-forming tissue, such as bone marrow, or immune system cells, such as leukemia, lymphoma, multiple myeloma, and others. Multiple myeloma medications are often used to treat various myeloma by killing and limiting the growth of cancer cells by decreasing the process of cell division by stimulating numerous enzymatic actions and assisting bones to stay strong and reducing pain in the weakening bone. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based health organization dedicated to eliminating cancer, there were approximately 59,610 newly diagnosed cases of leukemia and around 20,380 cases of acute myeloid leukemia (AML). Additionally, the total number of deaths attributed to leukemia amounted to 23,710. Therefore, the increasing prevalence of hematological cancer is driving the growth of multiple myeloma drugs market.

Product innovation is a key trend gaining popularity in the multiple myeloma drugs market. Major companies operating in the multiple myeloma drugs market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in March 2022, Janssen Biotech Inc., a Japan-based biotechnology company, received the United States Food and Drug Administration approval for Carvykti, a CAR T-Cell therapy (personalized immunotherapy) for multiple myeloma. CARVYKTI (ciltacabtagene autoleucel) is a genetically modified autologous cell-based product composed of T cells transduced ex vivo with a replication-incompetent lentiviral vector encoding an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) consisting of two single domain antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. Patients who have received four or more lines of therapy, including treatment with three critical kinds of multiple myeloma medications (an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody), are eligible to receive it to treat relapsed conditions.

Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:
Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB

Multiple Myeloma Drugs Market 2024 Key Insights:
• The multiple myeloma drugs market size is expected to see strong growth in the next few years. It will grow to $28.07 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%.
• Soaring Prevalence Of Hematological Cancer Fuels Expansion
• Janssen Biotech Introduces Carvykti, A Groundbreaking Car T-Cell Therapy
• North America was the largest region in the multiple myeloma drugs market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=11943&type=smp

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Multiple Myeloma Drugs Market Report 2024 - Multiple Myeloma Drugs Market Growth, Opportunities And Trends here

News-ID: 3763518 • Views:

More Releases from The Business research company

Global Subcutaneous Immunoglobulin (SCIG) Market Projected to Grow at 12.7% CAGR, Reaching $23.23 Billion by 2029
Global Subcutaneous Immunoglobulin (SCIG) Market Projected to Grow at 12.7% CAGR …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Subcutaneous Immunoglobulin (SCIG) Industry Market Size Be by 2025? The market for subcutaneous immunoglobulin (SCIG) has seen a swift expansion in the recent past. The market size is projected to escalate from $12.72 billion in 2024 to $14.39 billion in 2025, reflecting a compound annual growth
2025-2034 Ranibizumab Market Roadmap: Insights for Competitive Advantage
2025-2034 Ranibizumab Market Roadmap: Insights for Competitive Advantage
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Ranibizumab Market Size By 2025? The market for ranibizumab has experienced steady expansion in the past few years, with projections stating it will increase from $2.66 billion in 2024 to $2.76 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.6%. The growth
Emerging Peptide And Oligonucleotide CDMO Market Trends: Strategic Partnerships In Peptide And Oligonucleotide CDMO Market Boost Technological Capabilities And Market Reach Shaping the Future of the Industry
Emerging Peptide And Oligonucleotide CDMO Market Trends: Strategic Partnerships …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Peptide And Oligonucleotide CDMO Market Size Growth Forecast: What to Expect by 2025? In recent years, the peptide and oligonucleotide cdmo market has witnessed a swift escalation in its size. From $2.16 billion in 2024, it is projected to surge up to $2.42 billion in 2025 with a compound
Oral Solid Dosage Pharmaceutical Formulation: Critical Driver Shaping the Chronic Disease Prevalence Drive Growth In The Oral Solid Dosage Pharmaceutical Formulation Market Market in 2025
Oral Solid Dosage Pharmaceutical Formulation: Critical Driver Shaping the Chroni …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Oral Solid Dosage Pharmaceutical Formulation Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market for oral solid dosage pharmaceutical formulations has seen robust growth in the last few years. Its size is expected to increase from $618.34 billion in 2024 to $653.26 billion in

All 5 Releases


More Releases for Multiple

Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market. Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386 Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983 This latest report researches the industry structure,
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)